NO963785L - Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser - Google Patents

Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser

Info

Publication number
NO963785L
NO963785L NO963785A NO963785A NO963785L NO 963785 L NO963785 L NO 963785L NO 963785 A NO963785 A NO 963785A NO 963785 A NO963785 A NO 963785A NO 963785 L NO963785 L NO 963785L
Authority
NO
Norway
Prior art keywords
related conditions
treatment
5ht2b receptor
receptor
5ht2b
Prior art date
Application number
NO963785A
Other languages
English (en)
Other versions
NO963785D0 (no
Inventor
James Edmund Audia
Stephen Richard Baker
Marlene Lois Cohen
Jaswant Singh Gidda
David Lloyd Garver Nelson
Jesus Ezquerra-Carrera
Carlos Lamas-Pateira
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/380,565 external-priority patent/US5663178A/en
Priority claimed from US08/380,566 external-priority patent/US5688807A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO963785D0 publication Critical patent/NO963785D0/no
Publication of NO963785L publication Critical patent/NO963785L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det blir beskrevet fremgangsmåter for binding av en 5- HT2B resepter hos pattedyr ved anvendelse av både kjente og nye forbindelser. Videre blir det fremskaffet en fremgangsmåte for behandling eller forhindring av 5- HTgg relaterte tilstander. Endelig, fremskaffer foreliggende oppfinnelse en fremstilt artikkel.
NO963785A 1994-03-11 1996-09-10 Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser NO963785L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21262294A 1994-03-11 1994-03-11
US08/380,565 US5663178A (en) 1995-02-06 1995-02-06 Tetrahydro-beta carbolines
US08/380,566 US5688807A (en) 1994-03-11 1995-02-06 Method for treating 5HT2B receptor related conditions
PCT/US1995/003099 WO1995024200A1 (en) 1994-03-11 1995-03-10 Method for treating 5ht2b receptor related conditions

Publications (2)

Publication Number Publication Date
NO963785D0 NO963785D0 (no) 1996-09-10
NO963785L true NO963785L (no) 1996-11-01

Family

ID=27395770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963785A NO963785L (no) 1994-03-11 1996-09-10 Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser

Country Status (11)

Country Link
EP (1) EP0749313A4 (no)
JP (1) JPH09510216A (no)
CN (1) CN1148340A (no)
AU (1) AU679635B2 (no)
CA (1) CA2185236A1 (no)
CZ (1) CZ264996A3 (no)
FI (1) FI963571L (no)
HU (1) HUT75522A (no)
IL (1) IL112958A0 (no)
NO (1) NO963785L (no)
WO (1) WO1995024200A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
WO1996032944A1 (en) * 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
AU724646B2 (en) * 1996-03-15 2000-09-28 Eli Lilly And Company Method of treating common cold or allergic rhinitis
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
CZ298398A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
EP0942722B1 (en) * 1996-03-25 2004-05-19 Eli Lilly And Company Tetrahydro-beta-carboline compounds
WO2000069437A1 (en) 1999-05-18 2000-11-23 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
ES2244438T3 (es) 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用
WO2006085510A1 (ja) * 2005-02-08 2006-08-17 Astellas Pharma Inc. 過敏性腸症候群の治療薬
CA2617473A1 (en) 2005-08-08 2007-02-15 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
EP1988075B1 (en) 2006-02-20 2012-01-25 Astellas Pharma Inc. Pyrrole derivative or salt thereof
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
MX2011005221A (es) 2008-11-21 2011-08-03 Raqualia Pharma Inc Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
CN102711467A (zh) * 2009-09-23 2012-10-03 梅迪维新技术公司 吡啶并[3,4-b]吲哚类及使用方法
US9079904B2 (en) 2009-09-23 2015-07-14 Medivation Technologies, Inc. Pyrido[3,4-B]indoles and methods of use
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
MX2021010198A (es) * 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
AU2021337466A1 (en) * 2020-09-01 2023-03-30 Enveric Biosciences Canada Inc. Halogenated psilocybin derivatives and methods of using
CN117677618A (zh) * 2021-04-23 2024-03-08 吉尔伽美什制药公司 新颖的麦角灵类和治疗心境障碍的方法
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023143393A1 (zh) * 2022-01-29 2023-08-03 上海科技大学 三并环类化合物、其制备方法和用途
WO2025137581A1 (en) * 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
DE3240514A1 (de) * 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4520024A (en) * 1983-02-11 1985-05-28 Eli Lilly And Company Method of selectively blocking peripheral vascular serotonergic receptors
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.

Also Published As

Publication number Publication date
CA2185236A1 (en) 1995-09-14
AU679635B2 (en) 1997-07-03
CZ264996A3 (cs) 1998-01-14
IL112958A0 (en) 1995-06-29
FI963571A7 (fi) 1996-11-08
FI963571L (fi) 1996-11-08
JPH09510216A (ja) 1997-10-14
CN1148340A (zh) 1997-04-23
HUT75522A (en) 1997-05-28
EP0749313A4 (en) 2001-10-24
EP0749313A1 (en) 1996-12-27
NO963785D0 (no) 1996-09-10
HU9602482D0 (en) 1996-11-28
AU2118695A (en) 1995-09-25
FI963571A0 (fi) 1996-09-10
WO1995024200A1 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
NO961173L (no) Nye pyrido(3,2-e)pyrazinoner med antiastmatisk virkning og fremgangsmåte for deres fremstilling
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
DE69632293D1 (de) Verfahren zur Herstellung von Polysiloxan-Polycarbonat-Blockcopolymeren
DE69701714D1 (de) Verfahren zur behandlung von glassubstraten
NO991993L (no) FremgangsmÕte for trykkbehandling av plater
NO942056D0 (no) Fremgangsmåte ved polymerisering av C4-40- og med andre
ATE168131T1 (de) T-cadherin-bindungsmolekül
DE59609850D1 (de) Verfahren zur Herstellung von Vanillin und dafür geeignete Mikroorganismen
NO965476L (no) Fremgangsmåte for overflatebehandling av substrat og substrat overflatebehandlet ved fremgangsmåten
AU1074397A (en) Method for treating anxiety
AU6407094A (en) Method of treating tumors with antibodies
ATE232919T1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69201530D1 (de) Verfahren zur Herstellung von Ethylen-Propylen-Blockkopolymerisate.
DE69735433D1 (de) Verfahren zur herstellung von substituierten pyridinen
DK0805806T3 (da) Fremgangsmåde til fremstilling af 4,10-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxotax-11-en-13alpha-
EP0909172A4 (en) METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
AU617252B2 (en) Method of treating tinea
FI973173L (fi) Menetelmä kondensaatin käsittelemiseksi
AU7726396A (en) Method for treating anxiety
EP0711159A4 (en) METHODS AND COMPOSITIONS FOR TREATING ASTHMA, ATHEROSCLEROSIS AND INFLAMMATORY DISEASE USING OPTICALLY PURE (-) - ZILEUTON
NO982582L (no) Fremgangsmaate for behandling av smerte
NO960307D0 (no) Fremgangsmåte ved fremstilling av substituerte 4,6-diamino-5-cyanopyrimidiner
FI933961A7 (fi) Menetelmä kiintoaineiden käsittelemiseksi korkeassa lämpötilassa
DE69708226D1 (de) Verfahren zum Herstellen von kornorientierten Siliziumstahlblechen